Furthermore, we observed that Trp53 and Myh4 inactivation altered the spectrum of cancers arising in the mouse model toward adenocarcinomas, rather than the sarcomas that are typical of p53 inactivation alone. This evidence concerns the gene MYH4 and sarcoma.